Attached files

file filename
EX-99.1 - PRESS RELEASE - ACURA PHARMACEUTICALS, INCnewsrelease.htm

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934

July 1, 2011
Date of Report (Date of earliest event reported)


Acura Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)


State of New York
 
1-10113
 
11-0853640
(State or other jurisdiction
of incorporation)
  (Commission File Number)   (IRS Employer
Identification No.)


616 N. North Court, Suite 120
Palatine, Illinois   60067
(Address of principal executive offices) (Zip Code)

(847) 705-7709
Registrant's telephone number, including area code:


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

  [   ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  [   ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  [   ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  [   ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events.

On July 1, 2011 we issued a press release, furnished herewith as Exhibit 99.1, announcing that we received a $20 Million milestone payment from Pfizer, Inc. (Pfizer) triggered by the U.S. Food and Drug Administration's previously announced approval of Pfizer's New Drug Application for OXECTA(TM) (Oxycodone HCl, USP) Tablets CII.

Item 9.01. Financial Statements and Exhibits.

Exhibit
Number
Description

99.1 Press Release dated July 1, 2011


SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Acura Pharmaceuticals, Inc.

Date: July 1, 2011 By:   /s/   PETER A. CLEMENS
Peter A. Clemens
Senior Vice President & Chief Financial Officer



EXHIBIT INDEX


Exhibit
Number
Description

99.1 Press Release dated July 1, 2011